Quarterly ResultMay 7, 2026, 04:34 PM
Crinetics Q1 Revenue $10.7M; Net Loss $(127.8)M; $380M Stock Offering
AI Summary
Crinetics Pharmaceuticals reported a significant increase in total revenue to $10.7 million for Q1 2026, primarily driven by the launch of its first commercial product, PALSONIFY, in the U.S. The company also completed an underwritten public offering in January 2026, generating approximately $380 million in net proceeds, substantially enhancing its liquidity. Despite the revenue growth, the net loss widened to $127.8 million, reflecting increased operating expenses, particularly in research and development and selling, general, and administrative activities.
Key Highlights
- Total revenue increased to $10.7 million in Q1 2026 from $0.4 million in Q1 2025.
- Product revenue, net, was $10.3 million in Q1 2026, up from $0 in Q1 2025 due to PALSONIFY launch.
- Net loss widened to $(127.8) million in Q1 2026 from $(96.8) million in Q1 2025.
- Net loss per share was $(1.23) in Q1 2026, compared to $(1.04) in Q1 2025.
- Completed a public offering in January 2026, raising approximately $380 million in net proceeds.
- Cash, cash equivalents, and investment securities totaled $1.3 billion as of March 31, 2026.
- Research and development expenses rose to $100.1 million from $76.2 million year-over-year.
- Selling, general and administrative expenses increased to $50.8 million from $35.5 million year-over-year.